InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.810 0.015 (1.89%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$386 Starpharma to commence DEP cabazitaxel phase 1/2 trial 31 Jan 2018 10:54AM $1.615 $0.810 fallen by 49.85%
$386 Appendix 3B 29 Jan 2018 3:24PM $1.580 $0.810 fallen by 48.73%
$386 Appendix 4C - Quarterly Cashflow Report 25 Jan 2018 9:38AM $1.440 $0.810 fallen by 43.75%
$386 VivaGel BV treatment clinical submission under rolling NDA 21 Dec 2017 10:29AM $1.340 $0.810 fallen by 39.55%
$386 Change in Director's Interest Notice - J Fairley 11 Dec 2017 5:15PM $1.380 $0.810 fallen by 41.30%
$386 Appendix 3B 11 Dec 2017 5:08PM $1.380 $0.810 fallen by 41.30%
$386 Change in Director's Interest Notice - R Thomas 5 Dec 2017 5:03PM $1.375 $0.810 fallen by 41.09%
$386 Amended Constitution 29 Nov 2017 5:07PM $1.460 $0.810 fallen by 44.52%
$386 AGM Results 29 Nov 2017 5:00PM $1.460 $0.810 fallen by 44.52%
$386 AGM - Chairman address and CEO presentation 29 Nov 2017 12:55PM $1.398 $0.810 fallen by 42.04%
$386 NDA submission for VivaGel BV in the US 21 Nov 2017 10:55AM $1.445 $0.810 fallen by 43.94%
$386 Change in Director's Interest Notice - J Fairley 8 Nov 2017 9:43AM $1.410 $0.810 fallen by 42.55%
$386 Change in Director's Interest Notice - R Thomas 31 Oct 2017 11:04AM $1.360 $0.810 fallen by 40.44%
$386 Notice of Annual General Meeting/Proxy Form 27 Oct 2017 10:55AM $1.355 $0.810 fallen by 40.22%
$386 Appendix 4C - Quarterly Cashflow Report 26 Oct 2017 9:43AM $1.400 $0.810 fallen by 42.14%
$386 VivaGel BV granted marketing approval in Australia 25 Oct 2017 9:07AM $1.340 $0.810 fallen by 39.55%
$386 Shareholder Update October 2017 18 Oct 2017 11:00AM $1.335 $0.810 fallen by 39.33%
$386 Appendix 3B 12 Oct 2017 3:08PM $1.410 $0.810 fallen by 42.55%
$386 Starpharma and Peter Mac Cancer Centre awarded DEP Grant 9 Oct 2017 1:13PM $1.405 $0.810 fallen by 42.35%
$386 Change in Director's Interest Notice - J Fairley 5 Oct 2017 2:09PM $1.305 $0.810 fallen by 37.93%
$386 Appendix 3B 5 Oct 2017 2:06PM $1.305 $0.810 fallen by 37.93%
$386 Notification of AGM date 2 Oct 2017 4:39PM $1.335 $0.810 fallen by 39.33%
$386 AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor 28 Sep 2017 11:49AM $1.270 $0.810 fallen by 36.22%
$386 DEP docetaxel positive phase 1 results, phase 2 commences 22 Sep 2017 10:30AM $1.050 $0.810 fallen by 22.86%
$386 Appendix 4G - Corporate Governance Statement 28 Aug 2017 9:23AM $0.935 $0.810 fallen by 13.37%

526 - 550 of 884 results

Page 22 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.